Biocon Limited (NSE:BIOCON)
India · Delayed Price · Currency is INR 426.00
+0.65 (0.15%)
Jul 31, 2026, 3:30 PM IST
Biocon Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 169,270 | 152,617 | 147,557 | 111,742 | 81,840 | |
Revenue Growth | 10.91% | 3.43% | 32.05% | 36.54% | 14.57% |
Cost of Revenue | 66,606 | 60,176 | 55,822 | 42,125 | 31,729 |
Gross Profit | 102,664 | 92,441 | 91,735 | 69,617 | 50,111 |
Selling, General & Admin | 39,244 | 34,948 | 28,514 | 23,321 | 20,531 |
Research & Development | -1,137 | -1,476 | -838 | -3,922 | -4,764 |
Other Operating Expenses | 27,769 | 26,638 | 30,526 | 23,434 | 14,611 |
Operating Expenses | 85,721 | 77,010 | 73,901 | 53,974 | 38,528 |
Operating Income | 16,943 | 15,431 | 17,834 | 15,643 | 11,583 |
Interest Expense | -9,648 | -8,877 | -9,744 | -4,190 | -676 |
Interest & Investment Income | 1,154 | 1,115 | 1,613 | 1,124 | 1,121 |
Earnings From Equity Investments | - | - | -842 | -1,670 | -2,069 |
Currency Exchange Gain (Loss) | -1,799 | -562 | -523 | -1,605 | 579 |
Other Non Operating Income (Expenses) | 384 | -86 | 4,288 | 39 | 7 |
EBT Excluding Unusual Items | 7,034 | 7,021 | 12,626 | 9,341 | 10,545 |
Merger & Restructuring Charges | -1,372 | - | - | -470 | - |
Gain (Loss) on Sale of Investments | 1,632 | 383 | 2,754 | 2,596 | 420 |
Gain (Loss) on Sale of Assets | -158 | 10,497 | -12 | -52 | -23 |
Asset Writedown | - | -86 | -3,945 | - | - |
Other Unusual Items | -2,657 | 1,051 | 3,829 | -2,444 | -1,111 |
Pretax Income | 4,479 | 18,866 | 15,252 | 8,971 | 9,831 |
Income Tax Expense | 791 | 4,572 | 2,274 | 2,541 | 2,115 |
Earnings From Continuing Operations | 3,688 | 14,294 | 12,978 | 6,430 | 7,716 |
Net Income to Company | 3,688 | 14,294 | 12,978 | 6,430 | 7,716 |
Minority Interest in Earnings | 168 | -4,161 | -2,753 | -1,803 | -1,232 |
Net Income | 3,856 | 10,133 | 10,225 | 4,627 | 6,484 |
Net Income to Common | 3,856 | 10,133 | 10,225 | 4,627 | 6,484 |
Net Income Growth | -61.95% | -0.90% | 120.99% | -28.64% | -12.44% |
Shares Outstanding (Basic) | 1,366 | 1,197 | 1,195 | 1,193 | 1,191 |
Shares Outstanding (Diluted) | 1,369 | 1,198 | 1,197 | 1,196 | 1,196 |
Shares Change | 14.22% | 0.11% | 0.08% | -0.04% | -0.03% |
EPS (Basic) | 2.82 | 8.46 | 8.55 | 3.88 | 5.44 |
EPS (Diluted) | 2.82 | 8.46 | 8.54 | 3.87 | 5.42 |
EPS Growth | -66.67% | -0.94% | 120.67% | -28.60% | -12.44% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 1,961 | 19,246 | 12,734 | 2,565 | -5,212 |
Free Cash Flow Per Share | 1.43 | 16.06 | 10.64 | 2.15 | -4.36 |
Dividend Per Share | 0.500 | 0.500 | 0.500 | 1.500 | 0.500 |
Dividend Growth | 0% | 0% | -66.67% | 200.00% | - |
Gross Margin | 60.65% | 60.57% | 62.17% | 62.30% | 61.23% |
Operating Margin | 10.01% | 10.11% | 12.09% | 14.00% | 14.15% |
Profit Margin | 2.28% | 6.64% | 6.93% | 4.14% | 7.92% |
Free Cash Flow Margin | 1.16% | 12.61% | 8.63% | 2.30% | -6.37% |
EBITDA | 35,306 | 31,239 | 32,711 | 26,567 | 19,564 |
EBITDA Margin | 20.86% | 20.47% | 22.17% | 23.77% | 23.91% |
D&A For EBITDA | 18,363 | 15,808 | 14,877 | 10,924 | 7,981 |
EBIT | 16,943 | 15,431 | 17,834 | 15,643 | 11,583 |
EBIT Margin | 10.01% | 10.11% | 12.09% | 14.00% | 14.15% |
Effective Tax Rate | 17.66% | 24.23% | 14.91% | 28.32% | 21.51% |
Revenue as Reported | 172,695 | 164,699 | 156,212 | 115,501 | 83,967 |
Advertising Expenses | 3,911 | 3,309 | 1,870 | 1,482 | 1,692 |